A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Public ClinicalTrials.gov record NCT01325441. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Study identification
- NCT ID
- NCT01325441
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Enrollment
- 565 participants
Conditions and interventions
Conditions
Interventions
- BBI608 Drug
- Paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2011
- Primary completion
- May 31, 2021
- Completion
- May 31, 2021
- Last update posted
- Nov 14, 2023
2011 – 2021
United States locations
- U.S. sites
- 17
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC - University of Southern California Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Rocky Mountain Cancer Centers | Denver | Colorado | 80218 | — |
| Indiana University Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| Massachusetts General Hospital Cancer Center | Boston | Massachusetts | 02114 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169 | — |
| New York Oncology Hematology, P.C. | Albany | New York | 12206 | — |
| Ohio State University Wexner Medical Center | Columbus | Ohio | 43210 | — |
| Abramson Cancer Center of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Prisma Health (formerly Institute for Translational Oncology Research) | Greenville | South Carolina | 29605 | — |
| University of Tennessee Medical Center Cancer Institute | Knoxville | Tennessee | 37920 | — |
| Texas Oncology- Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Texas Oncology- Fort Worth | Fort Worth | Texas | 76104 | — |
| Texas Oncology- Tyler | Tyler | Texas | 75702 | — |
| Virginia Cancer Specialists, P.C. | Fairfax | Virginia | 22031 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Compass Oncology- Northwest Cancer Specialists | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01325441, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 14, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01325441 live on ClinicalTrials.gov.